Novartis Gleevec Gains Five Orphan Cancer Indications

Simultaneous approvals add a solid tumor cancer and four blood disorders to the targeted oncologic’s labeling, for a total of seven indications in five years.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet